

Index

- accidental exposure to HCV 165
- activation protein 1 (AP-1) 82
- acute HCV infections
 - in chimpanzees and humans 60–1
 - clinical aspects 97
 - factors affecting outcome 70–1, 74, 76
 - IFN treatment 102
 - natural history 61–3
 - virus concentrations in sera 164
 - see also* pathogenesis of HCV infections; treatment of HCV infections
- adeno-associated virus vectors 137
- adenovirus vectors 137, 138
- age at infection and HCV liver disease 57, 58
- alanine aminotransferase (ALT)
 - in acute infections 61, 97, 98
 - in chronic infections 61, 62, 98
 - in HCV diagnosis 14–15
 - IFN treatment and levels of 101
 - prognostic value 98–9
 - surrogate marker of NANBH 9, 10
- alcohol and HCV liver disease 57, 58–9, 63
- animal models of HCV infection 119–22
 - see also* chimpanzees; mouse models
- antibodies
 - anti-core antibodies (anti-HBc) 9, 10
 - assays for HCV *see* detection of HCV infections
 - bifunctional antibodies in gene therapy 138
 - to envelope glycoproteins (E1/E2) 73
 - importance in pathogenesis 75
 - to other HCV antigens 74
 - not predictive of acute infection outcome 72–3
- anti-D immunoglobulin-associated outbreaks 55–6
- antigens used in anti-HCV tests 12
- antisense oligonucleotides 130, 134, 136
- antiviral drugs
 - discovery and screening 131–4
 - resistance to 133
- antiviral gene therapy *see* gene therapy for HCV infections
- apoptosis
 - Fas-mediated 78–9
 - HCV core protein and 68, 82, 83, 86, 169
- asialoglycoprotein receptors in gene therapy 138
- assays for HCV *see* detection of HCV infections
- asymmetric gap ligase chain reaction 148
- AUG codons 22, 23
- autoantibodies
 - in chronic HCV infection 93, 94
 - produced during IFN treatment 104–5
- autocatalytic cleavage of NS2–NS3 22, 27–8, 29, 30, 34
- autoimmune diseases and HCV 12–13, 93–6
- autoimmune hepatitis 12–13, 93
- B cell malignancies and HCV 94–5, 170
- B cell responses to HCV infections 70
 - quasispecies selection 73, 74
 - see also* antibodies
- B cells, CD81 33
- Bcl-2 170
- bifunctional antibodies in gene therapy 138
- blood, HCV quasispecies diversity in 49
- blood donor screening
 - HCV RNA 16
 - serological 12, 13, 41–3
 - surrogate NANBH markers 9, 10
 - universal screening for HCV 164–5
- blood fractions
 - in HCV transmission 42, 43
 - virus inactivation in 50, 51

250 Index

- branched chain signal amplification (bdNA)
 - assay 148
- buoyant density of HCV 7, 19, 20, 161
- burden of HCV disease 45
- β -catenin mutations 91
- CD4⁺ T cells
 - activation 69, 70
 - in HCV/HIV coinfecting hemophiliacs 66
 - mediation of hepatocellular damage 71
- CD8⁺ T cells
 - in Fas-mediated hepatocyte killing 78
 - mediation of hepatocellular damage 71
- CD81 in HCV attachment 33
- cell types supporting HCV replication
 - in vitro 113–16
 - in vivo 113
 - see also* tissue culture replication of HCV
- Centers for Disease Control and Prevention (CDC) recommendations 52–3
- children, HCV response to IFN treatment 102
- chimpanzees
 - antibody responses to HCV 72–3
 - early studies of NANBH 4, 6–9
 - in HCV vaccine research 124–5
 - high HCV titer serum pool production 10
 - natural history of HCV infection in 59, 60–1, 117
 - utility as HCV infection models 119, 122
- chloroform sensitivity of NANBH agents 7, 8
- chronic HCV infections
 - alanine aminotransferase in 97–9
 - in chimpanzees and humans 60
 - clinical aspects 98
 - cytotoxic T cells in immunopathogenesis of 74, 76–8
 - factors leading to 168–9
 - health care costs (USA) 45
 - natural history 61–3
 - symptoms 99
 - T cell proliferative response 76
 - T helper response 69–71, 74–5
 - see also* autoimmune diseases and HCV; pathogenesis of HCV infections; treatment of HCV infections
- chronic liver disease (CLD) 45
 - alcohol exacerbation 57, 63
 - deaths from (USA) 45
 - HBV 5, 98
 - and HCV subtype 90
 - quasispecies diversity and 50
 - time to onset of symptoms (HCV) 98
- cirrhosis in chronic HCV infection
 - frequency of progression to 55, 62, 63
 - host factors 58–9
 - pegylated IFN treatment 130
 - risk factor for hepatocellular carcinoma 85–6
 - time scale of progression to 55, 62, 63
- classification of HCV 20
- CLD *see* chronic liver disease
- clinical course of HCV infections 97–9
- cloning of HCV (initial) 11
- COBAS AMPLICOR system 147
- conjunctival transmission of HCV 162
- consensus clone of HCV 117
- conservation of the 5' UTR 23, 47–8
- copy-back replication 39, 158
- core protein of HCV
 - in anti-HCV assays 13, 14
 - antisense oligonucleotides against 136
 - binding to cellular proteins 83
 - expression and HCV replication 31
 - expression in transgenic rodents 120
 - HBV suppression by in coinfections 82
 - in hepatocarcinogenesis 82–3, 86–7, 169
 - intracellular immunization against 135–6
 - and lipids 33–4
 - location in the polyprotein 21, 22
 - nuclear localization in transfected cells 82
 - potential antiviral target 134
 - RNA helicase stimulation 84
 - truncated forms 81
 - two mature polypeptide forms 26–7
 - vaccine research and 125, 126, 173
 - in virion assembly and uncoating 33, 37
- counseling patients 163–4
- crystallographic analysis of NS3 29–30
 - in rational drug design 131
- CTLs *see* cytotoxic T lymphocytes
- cysteine protease of NS2/NS3 protease 27
- cytokine gene therapy 138–9
- cytopathic effects of HCV infection 65–8, 83
- cytoplasmic tubules in NANBH livers 7, 8
- cytotoxic T lymphocytes (CTLs)
 - HCV clearance from liver 168
 - in HCV immunopathogenesis 74, 76–8
 - quasispecies distribution and 49–50
- defective interfering particles 16, 49

251 Index

- detection of HCV infections
 - alanine aminotransferase 14–15, 61–2, 97–8, 98–9
 - algorithm 15
 - antibody assays 12–14
 - confirmatory tests 14
- detection of HCV RNA 15–17
 - asymmetric gap ligase chain reaction 148
 - branched chain signal amplification 148
 - gel shift analysis 150
 - nucleic acid sequence-based amplification 148
 - real-time PCR 146–7
 - RT/PCR 31, 143–50
 - transcription-mediated amplification system 147–8
 - universal screening of blood donors 164–5
 - utility of 16–17
- diagnosis of HCV infections *see* detection of HCV infections
- disulfide bonding in NS5B 38
- DNA vaccination 125–6
- double-stranded RNA-induced protein kinase (PKR) 88, 108–9, 170
- drug resistance 133

- E-cadherin 91
- endoplasmic reticulum in HCV replication 31–2, 33–4
- envelope glycoproteins (E1/E2) of HCV
 - E2 binding to CD81 33
 - E2 genetic mutations and IFN resistance 107
 - E2 inhibition of PKR protein kinase 108
 - expression in transgenic mice 120
 - folding at the endoplasmic reticular membrane 34
 - genetic mutations in 48
 - location in the polyprotein 21, 22
 - virus-neutralizing antibodies 73, 123, 124–5
- enzyme-linked immunosorbent assay (ELISA) 12
- epidemiology of HCV infections
 - before the discovery of HCV 41
 - blood donor seroprevalences 41–4
 - burden of disease 45
 - public health surveillance 53
 - see also* prevention of HCV infections; transmission of HCV infections
- essential mixed cryoglobulinemia 93, 94, 170
- eucaryotic initiation factor 3 25

- extrahepatic HCV infection 113, 169

- false-positive anti-HCV tests 13, 14
- Fas-mediated killing 78–9
- α -fetoprotein promotor in gene therapy 139
- fixed mutation rates of HCV 46–8
- flaviviruses
 - cytopathic effects 65, 67
 - relationship with HCV 20, 21
- fulminant hepatitis 78, 168

- GDD motif 37, 38
- gel shift analysis 150
- gender and cirrhosis development 58
- gene expression in HCV 30–1, 129
- gene therapy for HCV infections
 - antisense oligonucleotides 136
 - bifunctional antibodies 138
 - cytokines 138–9
 - HCV-specific ribozymes 135
 - hepatocellular carcinoma treatment 139–40
 - intracellular immunization 135–6
 - vectors 137–8
- gene vaccination 125–6
- genetic heterogeneity of HCV 46
 - clinical significance 47
 - genotypes and subtypes 45
 - geographic distribution 45, 46
 - implications for vaccine development 123
 - mutation rates and 47–8
 - quasispecies *see* quasispecies of HCV
 - and replicative ability 166–7
 - and responses to IFN 103
 - and responses to IFN/ribavirin 106
 - subtype 1b and hepatocellular carcinoma 90, 103
 - typing methods 149
 - in 5' UTR 161–2, 166–7
- genetic mutations in hepatocellular carcinoma 90–1
- genome of HCV
 - comparison with other viral genomes 20–1
 - gene products 21–2
 - initial characterization 11
 - mutation frequency 32
 - UTRs *see* 3' untranslated region; 5' untranslated region
- genotypes and subtypes of HCV *see* genetic heterogeneity of HCV

252 Index

- HAV *see* hepatitis A virus
 HBV *see* hepatitis B virus
 HCC *see* hepatocellular carcinoma
 HCV discovery 10–11
 HCV RNA 3.0 Quantitative Assay 148
 helicase activity of NS3
 assays 154–5
 role in HCV replication 34
 screening of new antivirals against 131
 helper T cells *see* T helper cells
 hemodialysis in HCV transmission 42, 51, 52
 hepatitis A virus (HAV) 3–5, 97
 hepatitis B virus (HBV) 3–5
 acute infection 97
 anti-HBc as a surrogate marker of NANBH 9, 10
 chronic infection 97–8
 coinfection with HCV 57, 82
 compared with HAV and NANBH (HCV) 5
 HBV X antigen 57, 89
 occult infection 57, 88–9
 replication in transgenic mice 119–20, 121
 hepatitis B virus-like NANBH agents 4, 6, 9
 hepatitis E virus 6
 hepatitis G viruses 20, 21
 hepatocarcinogenesis and HCV
 core protein in 82–3, 86–7, 169
 mechanisms additional to HCV 90–1
 NS3 in 87–8
 NS5A in 36, 88, 89
 hepatocellular carcinoma
 gene therapy for 139–40
 genetic mutations 90–1
 in HCV core transgenic mice 120, 169
 HCV replication in 31, 86
 and HCV subtype 1b 90
 prevalence 85
 reduced in interferon responders 88, 102
 risk factors for 85–6, 88
 hepatocytes
 CD81 on 33
 cultured from chimpanzees with NANBH 7
 Fas-mediated killing 78
 HCV expression in 30–1
 HCV replication in vitro 171
 HCV replication in vivo 32
 retrovirus-like particles in 4
 transplantation of HBV-transfected 122
 herpes viruses, implicated in NANBH 6
 heteroduplex analysis 150
 heterogeneous nuclear ribonucleoprotein 26, 82
 human immunodeficiency virus (HIV)
 coinfection with HCV 42, 44, 57, 66
 HLA class II haplotype and outcome of HCV
 infection 71
 human–mouse radiation chimerae 122
 humoral immunity to HCV *see* B cell responses to
 HCV infections
 HVR *see* hypervariable regions
 hypergammaglobulinemia and anti-HCV assays
 13, 93
 hypervariable regions in the HCV genome 47,
 48, 73, 74
 IFN *see* interferon
 IgG1 isotype antibodies to HCV 74
 immune responses to HCV
 in chimpanzees and humans 60–1
 immunopathology of infections 67–71
 kinetics 63
 prognostic significance 167–8
 see also antibodies; B cell responses to HCV
 infections; T cell responses to HCV
 infections
 immunoglobulin/HCV complexes 19, 123
 immunotherapy for HCV infections 174
 infectious hepatitis (HAV) 3–5, 97
 infectivity of HCV and RNA detection 16
 in situ hybridization 30–1
 insulin-like growth factor II 90
 interferon gamma (IFN- γ) 69–70, 71, 108
 interferon treatment of HCV infections
 clinical trials 101–2
 combined with ribavirin 105–6
 mechanism(s) of action 170
 outcome prediction 103–4
 pegylated IFN 129–30
 resistance mediation by NS5A 107–9
 response of essential mixed cryoglobulinemia
 94
 side effects 104–5
 interferon inhibition of HCV replication in cell
 culture 116
 interferon sensitivity determining region (ISDR)
 36, 46, 107, 108
 internal ribosome entry site (IRES)
 antisense oligonucleotides against 136
 binding proteins 26
 genotype differences in translation efficiency
 162, 166–7

253 Index

- location in the 5' UTR 23
- secondary structure 24, 25
- in translation initiation 23, 25, 26
- international standard for HCV 147
- intracellular immunization 135–6
- intravenous drug abuse in HCV transmission 42–4, 52, 53
- IRES *see* internal ribosome entry site
- ISDR *see* interferon sensitivity determining region
- Jak/Stat pathway 108
- Kupffer cells 69, 171–2
- LDL *see* low density lipoproteins
- lentivirus vectors 137–8
- lichen planus 95
- ligase chain reaction 148
- liposomes in gene therapy 138
- liver, HCV quasispecies diversity in 49, 50
- liver cell cultures susceptible to HCV 114, 115
- liver disease
 - minimization of risks of development 163–4
 - see also* chronic liver disease
- liver transplantation, reinfection with HCV 17
- loss of heterozygosity 90–1
- low density lipoproteins 19, 33
- lymphoid cell cultures susceptible to HCV 114
- lymphotrophism of HCV 94, 95, 113, 162
- membrane targeting in HCV replication 31–2
- metal-binding domain of NS3 29–30
- microheterogeneity within HCV sequences 46, 47, 133
- minireplicons 115
- minus strand RNA 31, 151
- mother–infant transmission of HCV 17, 42, 44, 164
- mouse models
 - fulminant hepatitis 78
 - in vaccine research 125–6
 - see also* transgenic mice
- mutation rates of HCV 46, 47–8
- Myc in hepatocarcinogenesis 87
- NANBH *see* non-A, non-B hepatitis
- NASBA *see* nucleic acid sequence-based amplification assay
- natural history of HCV infection
 - acute infections 60–2
 - age at infection 57, 58
 - chronic infections 60, 61–3, 168–9
 - coinfection with HBV or HIV and 57
 - host factors in cirrhosis development 58–9
 - infectious clone studies 117
 - insights from chimpanzee models 59, 60–1, 117
 - longitudinal studies 55–6
 - outstanding issues 167
 - time scales 55, 58
- natural killer cells with T cell markers 69
- needlestick injuries 42, 165
- NKT *see* natural killer cells with T cell markers
- non-A, non-B hepatitis (NANBH)
 - candidate agents (non-HCV) 4, 6
 - chimpanzee studies (early) 4, 6–9
 - compared with HAV and HBV infections 5
 - cytopathic effects 65
 - diagnosis pre-HCV discovery 4
 - epidemiology pre-HCV discovery 41
 - low serum titer of agents 8, 11
 - size determination of agent(s) 7
 - surrogate markers 9–10
- noncoding regions of HCV *see* 3' untranslated region; 5' untranslated region
- nonHodgkin's lymphoma 94
- nonstructural (NS) proteins of HCV
 - locations in the polyprotein 21, 22
 - NS2–NS3 cleavage 27–8, 29, 30, 34
 - NS3–NS4A cleavage 28, 132, 166
- nonstructural protein 3 (NS3)
 - in anti-HCV assays 13, 14
 - in antiviral screening 131–3
 - enzyme activity assays 153–5
 - helicase *see* helicase activity of NS3
 - in hepatocarcinogenesis 87–8
 - low mutation rate 48
 - NTPase 22, 34, 154
 - protease inhibitors 132
 - roles in virus replication 34–5
 - serine protease *see* serine protease of NS3
 - zinc binding 29–30
- nonstructural protein 4A
 - cofactor of NS3 28–9, 32, 35
 - stimulation of NS5A phosphorylation 35
- nonstructural protein 4B 35
- nonstructural protein 5A 35–6
 - in hepatocarcinogenesis 88, 89
 - and IFN resistance 107–9
 - nuclear localization signal 36

- nonstructural protein 5A (*cont.*)
 outstanding questions about 162–3
 phosphorylation 35, 36, 162–3
 trans-activating activity 35, 36, 89, 107–8, 162–3
- nonstructural protein 5B (RNA-dependent RNA polymerase)
 characterization methods 37, 38, 157–8
 copy-back replication 39, 158
 expression in mammalian cells 158
 phosphorylation 38
 quasispecies and IFN efficacy 104
 in RNA synthesis 37
 screening of antivirals against 133
 secondary structure 37–8, 157
 template specificity 38, 163
 in vitro assays for 158
- NS *see* nonstructural proteins
- NTPase activity of NS3 22, 34, 154
- nucleic acid sequence-based amplification assay 148
- nucleocapsid of HCV 20, 22
- occupational exposure to HCV 44
- open reading frame of HCV RNA 21
- p7 21, 22
- p53 86, 87, 91
- pathogenesis of HCV infections
 core protein in 81–4
 cytopathic effects, evidence for and against 65–8, 83
 immunopathology 67, 68–71
 mechanisms of liver cell injury summarized 66
 prognostic significance of immune responses 167–8
 see also B cell responses to HCV infection; T cell responses to HCV infection
- PCR *see* polymerase chain reaction
- pegylated IFN (polyethylene glycol-modified IFN) 129–30
- perforin/granzyme system 79–80
- persistence of HCV infections 32, 50, 168–9
 see also chronic HCV infections; pathogenesis of HCV infections
- pestivirus 5' untranslated region 20
- phosphorylation
 of core protein 82
 of NS5A 35, 36, 162–3
 of NS5B 38
- physical heterogeneity of HCV 161
- picornaviruses, implicated in NANBH 6
- PKR protein kinase *see* double-stranded RNA-induced protein kinase
- polyethylene glycol-modified IFN *see* pegylated IFN
- polymerase chain reaction (PCR)
 asymmetric in quasispecies characterization 150
 real-time PCR 146–7
 see also reverse transcriptase/polymerase chain reaction
- polyprotein of HCV 21–2, 26–30
 see also individual gene products
- polypyrimidine tract binding protein (PTB) 26, 39
- prevention of HCV infections
 before the discovery of HCV 50
 CDC recommendations 52–3
 improved healthcare practices 51–2
 promotion of low-risk behaviors 52
 virus inactivation in blood fractions 51
 see also blood donor screening
- primary cells supporting HCV replication 113–15
- protease *see* serine protease activity of NS3
- PTB *see* polypyrimidine tract binding protein
- quasispecies of HCV 46, 47
 characterization methods 149–50
 in chronic HCV infection development 32, 73, 168–9
 and design of future therapeutics 174
 differences between liver and blood 49
 diversity and liver disease 49–50, 57
 diversity and response to IFN 103, 104
 factors affecting evolution 48–9
 replicative abilities in tissue culture 172
 selection by HCV antibodies 73, 74
- Rb* (retinoblastoma tumor suppressor gene) 91
- RdRp *see* nonstructural protein 5B
- real-time PCR 146–7
- recombinant HCV NS5A isolation 157–8
- recombinant immunoblot assay (RIBA) 12, 14, 15
- renal dialysis in HCV transmission 42, 51, 52
- renal support of HCV replication 113

255 Index

- replication complexes 21, 22, 37, 39, 163
- replication of HCV
 - attachment and entry 33
 - core protein and 33, 37
 - endoplasmic reticular membranes in 31–2, 33–4
 - envelope E1/E2 proteins and 34
 - inhibition by IFN in tissue culture 116
 - NS3 34–5
 - NS4A 35
 - NS5A 36, 163
 - NS5B 36–9, 163
 - packaging and budding 37
 - rate 32
 - RNA synthesis 37
 - 3' UTR in 40, 117
 - 5' UTR in 22–3, 25–6, 39
 - see also* tissue culture replication of HCV
- replicons 129
- retinoblastoma tumor suppressor gene (*Rb*) 91
- retroviruses, implicated in NANBH 4
- retrovirus vectors 137, 139
- reverse transcriptase/polymerase chain reaction (RT/PCR)
 - crossover contamination prevention 144
 - genotyping/subtyping using products 149
 - procedure 145–6
 - product detection 146
 - in quasispecies characterization 149–50
 - in situ 31
 - sample handling for 143
 - semiquantification 146
 - see also* polymerase chain reaction
- RIBA *see* recombinant immunoblot assay
- ribavirin (tribavirin) treatment of HCV infections
 - combined with IFN 105–6
 - combined with pegylated IFN 130
 - mechanisms of action 105
 - monotherapy 105
 - side effects 106
- ribosomal 40S subunit binding to HCV 5' UTR 25
- ribozymes in HCV gene therapy 135
- RNA of HCV
 - acute infections 62, 97
 - chronic infections 62
 - early characterization 11
 - infectious clones 117
 - plus and minus strand detection 31, 151
 - secondary structure 23–5, 40
 - synthesis 37
 - see also* detection of HCV RNA
- RNA helicase activity of NS3 22, 34, 35
- RNA-binding assays 155
- RNA-dependent RNA polymerase *see* nonstructural protein 5B
- Roche Amplicor kit 146
- RT/PCR *see* reverse transcriptase/polymerase chain reaction
- salivary glands 162
- sample handling for HCV RNA amplification 143–4
- SCID mice *see* severe combined immunodeficient mice
- secondary structure
 - NS5B protein 37–8, 157
 - 3' UTR RNA 40
 - 5' UTR RNA 23–5
- sequence heterogeneity of HCV *see* genetic heterogeneity of HCV
- serine protease activity of NS3
 - activation by NS4A 29
 - assays 153
 - in HCV polyprotein processing 22, 27, 28–9
 - screening antivirals against 131–3
- serum hepatitis *see* hepatitis B virus (HBV)
- severe combined immunodeficient mice 121
- sexual transmission of HCV 17, 42–4, 52, 164
- signal peptidase cleavage of HCV polyprotein 22, 26
- size determination, enveloped NANBH agent 7
- Sjögren's syndrome 95
- skin disorders and HCV 95
- storage of clinical samples 143
- structural proteins of HCV 22
 - see also* core protein of HCV; envelope glycoproteins (E1/E2) of HCV
- structure of HCV 20
- subgenomic replicons 129
- subtypes of HCV *see* genetic heterogeneity of HCV
- surrogate markers of NANBH 9–10
- SV40 vectors 138
- tamarins 119
- Taq polymerase 145
- TaqMan RT/PCR test 147

- T cell memory 77
 T cell proliferation assays 76
 T cell receptors 80, 81
 T cell responses to HCV infections 67, 69–71, 74, 75–81
 T helper cells
 Th1 69, 70, 71, 75
 Th2 70, 71, 75
 temperature-gradient gel electrophoresis 150
 TGF α *see* transforming growth factor α
 therapeutic vaccine research 124–6, 172–3
 therapy for HCV infections *see* treatment of HCV infections
 TIGRIS system 148
 tissue culture replication of HCV
 in antiviral screening 131, 132, 133
 difficulty in proving 151–2
 inconsistent levels 116
 reasons for poor results 171–2
 see also cell types supporting HCV replication
 tissue range of HCV 162
 trans-activating activity of NS5A 35, 36, 89, 107–8, 162–3
 transcription-mediated amplification system 147–8
 transfected cell lines 114–16
 transforming growth factor α 90
 transgenic mice
 HBV replication in 119–20
 HCV model development in 120
 severe combined immunodeficient 121
 transgenic rats, HCV gene expression in 120–1
 translation initiation in HCV 22–3, 25–6
 transmission of HCV infections
 blood transfusions/fractions 41–3
 intravenous drug abuse 42–4
 mother–infant 17, 44
 occupational exposure 44
 precautions to reduce 164
 risk factors summarized 42
 sexual 17, 43, 44
 see also prevention of HCV infections
 treatment of HCV infections
 combined IFN/ribavirin 105–6
 contraindications 171
 counseling 163–4
 DNA vaccination 125–6
 goals and prospects 173–4
 IFN *see* interferon treatment of HCV infections
 immunotherapy 174
 monitoring 106
 patients recommended for 170–1
 problem of late diagnosis 101
 ribavirin *see* ribavirin treatment of HCV infections
 vaccines 124–6, 172–3
 see also gene therapy for HCV infections
 tree shrews 119
 tribavirin *see* ribavirin
 Tth enzyme 146
 tumor necrosis factor receptor family, binding by
 HCV core 83
 ultrastructure of HCV 20
 3' untranslated region (3' UTR)
 binding by PTB 26
 role in virus replication 40, 117
 5' untranslated region (5' UTR)
 antisense oligonucleotides against 136
 binding by PTB 26, 39
 conservation 23, 47–8
 genetic heterogeneity 161–2, 166–7
 IRES *see* internal ribosome entry site
 potential antiviral target 134
 ribozymes against 135
 RT/PCR based on 146
 secondary structure 23–5
 translation initiation 22–3, 25–6
 unwindase (helicase) assays 154–5
 UTR *see* 3' untranslated region; 5' untranslated region
 vaccine research
 case for vaccine development 124
 chimpanzee work 124–5
 mouse work 125–6
 problems to be addressed 123, 172–3
 vectors for gene therapy 137–8
 viral load
 and HCV quasispecies 49
 and immune response 71, 75–6
 inverse correlation with cytotoxic T cell responses 77
 and response to IFN 103, 104
 and response to IFN/ribavirin 106
 Wnt signal transduction 91
 zinc
 in NS3 function 30
 stimulation of NS2–NS3 cleavage 27, 30